SA Article - 3 Things In Biotech You Should Learn
Post# of 72440
(Total Views: 208)
Posted On: 08/13/2017 7:30:42 PM
SA Article - 3 Things In Biotech You Should Learn Today: August 10, 2017
Innovation Pharmaceuticals nearing an endgame for an important trial
Innovation Pharmaceuticals (OTCQB:IPIX) is developing a novel antimicrobial agent called brilacidin for the prevention of severe oral mucositis, which is where the mucosal linings of the mouth break down due to some injury, leading to increased risk of infection and debilitating pain.
Mucositis is a common complication from local therapy for certain cancers, like head and neck squamous cell carcinoma, where radiation therapy is an important treatment option.
The news with IPIX is that it has completed enrollment of a phase 2 study assessing brilacidin as a preventative therapy for mucositis, and the company anticipates a top-line data readout in the fourth quarter of 2017.
Looking forward: The current standard of care for oral mucositis generally is pointed at alleviating symptoms, with nothing available to address the underlying infections that lead to the complication. Brilacidin looks like it could be an effective option in this line, so it is important for those who are following supportive care to keep up on news like this.
https://seekingalpha.com/article/4097221-3-th...st-10-2017
Innovation Pharmaceuticals nearing an endgame for an important trial
Innovation Pharmaceuticals (OTCQB:IPIX) is developing a novel antimicrobial agent called brilacidin for the prevention of severe oral mucositis, which is where the mucosal linings of the mouth break down due to some injury, leading to increased risk of infection and debilitating pain.
Mucositis is a common complication from local therapy for certain cancers, like head and neck squamous cell carcinoma, where radiation therapy is an important treatment option.
The news with IPIX is that it has completed enrollment of a phase 2 study assessing brilacidin as a preventative therapy for mucositis, and the company anticipates a top-line data readout in the fourth quarter of 2017.
Looking forward: The current standard of care for oral mucositis generally is pointed at alleviating symptoms, with nothing available to address the underlying infections that lead to the complication. Brilacidin looks like it could be an effective option in this line, so it is important for those who are following supportive care to keep up on news like this.
https://seekingalpha.com/article/4097221-3-th...st-10-2017
(1)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼